Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardio…

January 20, 2011 By Bio-Medicine.Org

CAMBRIDGE, Mass., Jan. 20, 2011 /PRNewswire/ — Pervasis
Therapeutics, Inc. today announced it will present interim data
from the company’s Phase 1/2 clinical study of PVS-10200, an
investigational cell-based therapy under development to prevent
restenosis in patients with peripheral arterial disease (PAD) who
undergo an angioplasty and stent procedure in the superficial
femoral artery. Jean-Marc Alsac, MD, Associate-Faculty in Vascular
Surgery, Department of Cardiovascular Surgery, Hopital Europeen
Georges Pompidou, Paris, and principal investigator of the study,
will present the findings at the Sixth Annual International
Conference on Cell Therapy for Cardiovascular Disease (IC3D) today
in New York City.

Dr. Alsac will report initial 6-month data from the open-label
dose escalation study designed to evaluate the safety, feasibility
and impact of PVS-10200 on the incidence of major adverse events.
Secondary endpoints include the rates of target lesion
revascularization, primary patency and restenosis.  In June
2010, Pervasis announced the first cohort of patients had been
fully enrolled in the study. Enrollment in a second cohort is
ongoing.  The study is being conducted at Hopital Europeen
Georges Pompidou, and two other hospitals in France, Hopital Bichat
and Centre Hospitalier Universitaire d’Amiens.

“Although most revascularization procedures of the superficial
femoral artery have high initial success rates, restenosis is a
common occurrence within a year after surgery, leading to poor
outcomes and the need for repeat procedures,” said Dr. Alsac. “I am
highly encouraged by the initial findings of the study. The low
rate and nature of adverse events reported thus far demonstrate the
potential of PVS-10200 as a safe, viable and minimally invasive
option to treat vascular injury and improve outcomes for
patients.”

Pervasis is a clinical stage company focused on developing
breakthrough therapies with the potential to improve outcom

‘/>”/>

SOURCE

Related Articles Read More >

Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions
Koya Medical’s Dayspring device
Koya Medical reports positive early results in Dayspring lymphedema trial

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech